Aqua Pharmaceuticals Welcomes David Crean as Vice President, Corporate Development

Aqua Pharmaceuticals Welcomes David Crean as Vice President, Corporate Development

WEST CHESTER, Pa.--(BUSINESS WIRE)--Nov 8, 2010 - West Chester-based Aqua Pharmaceuticals today announces the addition of David Crean as vice president, corporate development. In this role, Crean will be responsible for all of Aqua's acquisition, licensing and corporate initiatives.

"David brings with him a level of experience and understanding that will be of great benefit to the senior management team," said Jay Gooding, Aqua CEO. "His business development background along with his knowledge of dermatology within the pharmaceutical market make him ideal for this position. We are thrilled to have him on our team."

Crean joins Aqua following a senior director for business development position with Allergan, Inc., where he worked primarily in new business generation and transaction execution in support of growing many of Allergan's business units including topical facial aesthetics, therapeutic skin care and movement-related neurological disorders. Prior to his role in business development, David was the director of project and portfolio management, where he was responsible for leading critical drug development programs.

Crean holds a doctorate in biophysics from the State University of New York at Buffalo and a master's degree in business administration with a finance concentration from Pepperdine University.

About Aqua Pharmaceuticals

West Chester, Pennsylvania-based Aqua Pharmaceuticals is a specialty pharmaceutical company focusing on acquiring, developing and marketing prescription dermatology products. Aqua is a portfolio company of Roundtable Healthcare Partners, an operating-oriented private equity firm which has raised $1.9 billion in private equity funds and has invested more than $250 million in capital over the past year in healthcare related transactions. For more information, visit



Contact: Aqua Pharmaceuticals
Abbey Madden, 610-644-7000
[email protected]


Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.